Interim results of a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with FISH-amplified advanced or metastatic breast cancer

被引：0
|
作者：
Stein, S. H.
Gomez, H. L.
Chavez, M. A.
Doval, D. C.
Chow, L. W.
Newstat, B.
Berger, M. S.
Sledge, G. W.
机构：
[1] GlaxoSmithKline Inc, Med Dev Ctr Oncol, Collegeville, MN USA
[2] Inst Special Enfermedades Neoplasica, Lima, Peru
[3] Hosp Alberto Sabogal, Lima, Peru
[4] Rajiv Gandhi Canc Inst, Res Ctr, New Delhi, India
[5] Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[6] Indiana Univ, Indianapolis, IN 46204 USA
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：78 / 78
页数：1
相关论文
共 50 条
  • [1] Biomarker results from a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer
    Gomez, HL
    Chavez, MA
    Doval, DC
    Nag, S
    Chow, LW
    Ang, PC
    Ahmad, NM
    Berger, M
    Newstat, B
    Stein, S
    Sledge, GW
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S63 - S63
  • [2] Phase II clinical study of lapatinib (GW572016) in patients with advanced or metastatic breast cancer.
    Iwata, H.
    Toi, M.
    Fujiwara, Y.
    Ito, Y.
    Fujii, H.
    Nakamura, S.
    Aogi, K.
    Zaks, T.
    Sasaki, Y.
    Takashima, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S68
  • [3] Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
    Iqbal, S.
    Goldman, B.
    Fenoglio-Preiser, C. M.
    Lenz, H. J.
    Zhang, W.
    Danenberg, K. D.
    Shibata, S. I.
    Blanke, C. D.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2610 - 2615
  • [4] S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer
    Iqbal, S.
    Goldman, B.
    Lenz, H. J.
    Fenoglio-Preiser, C. M.
    Blanke, C. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer.
    Gomez, H. L.
    Chavez, M. A.
    Doval, D. C.
    Nag, S.
    Chow, L. W.
    Chang, P. C.
    Ahmad, N. M.
    Berger, M.
    Arbushites, M.
    Westlund, R.
    Stanislaus, M.
    Zaks, T.
    Stein, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S68
  • [6] Phase I study of lapatinib (GW572016) in combination with letrozole in cancer patients
    Chu, Q.
    Rowinsky, E.
    Goldstein, L.
    Cianfrocca, M.
    Murray, N.
    Gale, M.
    Ho, P. T.
    Loftiss, J. I.
    Paul, E.
    Pandite, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 119 - 119
  • [7] A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer
    Sridhar, Srikala S.
    Hotte, Sebastien J.
    Chin, Joseph L.
    Hudes, Gary R.
    Gregg, Richard
    Trachtenberg, John
    Wang, Lisa
    Tran-Thanh, Danh
    Pham, Nhu-An
    Tsao, Ming-Sound
    Hedley, David
    Dancey, Janet E.
    Moore, Malcolm J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (06): : 609 - 613
  • [8] Phase I study of lapatinib (GW572016) in combination with trastuzumab in advanced ErbB2-positive breast cancer
    Storniolo, A. M.
    Burris, H. A., III
    Pegram, M. D.
    Overmoyer, B.
    Miller, K.
    Jones, S. F.
    Silverman, P.
    Paul, E.
    Loftiss, J.
    Pandite, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 78 - 78
  • [9] Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer.
    Ross, HJ
    Blumenschein, GR
    Dowlati, A
    Aisner, J
    Rigas, JR
    Stanislaus, M
    Leopold, LH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 645S - 645S
  • [10] A phase II, open-label, multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing reimens
    Blackwell, Kimberly
    Kaplan, Edward H.
    Franco, Sandra X.
    Marcom, P. Kelly
    Maleski, Janet
    Sorensen, Mel
    Berger, Mark S.
    ANNALS OF ONCOLOGY, 2004, 15 : 27 - 27
12345